Latest News

BioCap2015

Thursday, 1 October 2015

BioCap2015 Conference 30th September 2015

We are excited to share the great news that Inhalosome-C Ltd won 1 of 10 places to ‘Pitch’ yesterday at the BioCap2015 Conference at Alderley Park Conference Centre.  BioCap2015 is the only life science and investment conference based in the North of England


Inhalosome-C successful in 2nd round

Saturday, 15 November 2014

Inhalosome-C Ltd submitted the 2nd round application for TSB Late Stage Biomedical Catalyst Fund with results coming out in the New Year 2015.


Inhalosome-C through to next round

Wednesday, 15 October 2014

Inhalosome-C Ltd successfully went through the first round of the application process of the TSB Late Stage Biomedical Catalyst Fund.


  • BioCap2015

    1 October 2015

    BioCap2015 Conference 30th September 2015

    We are excited to share the great news that Inhalosome-C Ltd won 1 of 10 places to ‘Pitch’ yesterday at the BioCap2015 Conference at Alderley Park Conference Centre.  BioCap2015 is the only life science and investment conference based in the North of England

  • Inhalosome-C successful in 2nd round

    15 November 2014

    Inhalosome-C Ltd submitted the 2nd round application for TSB Late Stage Biomedical Catalyst Fund with results coming out in the New Year 2015.

  • Inhalosome-C through to next round

    15 October 2014

    Inhalosome-C Ltd successfully went through the first round of the application process of the TSB Late Stage Biomedical Catalyst Fund.

About us

Inhalosome-C Ltd was founded to deliver Inhalosome-C’s promising health outcomes. Inhalosomes is a patented lipid based nanoparticle vesicle drug delivery technology for administrating drugs via the lungs developed by the University of Strathclyde.

Inhalosome-C uses the technology to deliver Cisplatin in lung cancer treatment. Cisplatin is already used as a lung cancer treatment administered intravenously currently for a broad range of cancers. Inhalosome-C allows non-invasive treatment of lung cancer and will dramatically improve the therapeutic outcome and quality-of-life.

IC Project

Inhalosomes is a patented lipid based nanoparticle vesicle drug delivery technology for administrating drugs to the lungs developed by the University of Strathclyde.

Initially Inhalosome-C is being developed to deliver Cisplatin to treat Non-Small Cell Lung Cancer (NSCLC). Cisplatin is already used as a lung cancer treatment and currently administered intravenously, which causies a number of side effects. Inhalosome-C allows the non-invasive treatment of NSCLC lung cancer and will dramatically improve the therapeutic outcome and quality-of-life…

Read more

Staff Members

  • Dr Tony Lockett MBBS, MBA, PhD

    Tony is a medical doctor specialising in the development of pharmaceuticals and devices.

    He has worked for over 20 years in this sector, and has developed and registered many pharmaceuticals. He has considerable experience in drug development, regulatory submissions and licensing deals. He is continues to advise a number of clients on drug development in respiratory and other diseases.

    Tony is the Medical Director responsible for driving and overseeing all aspects of this project.


  • Robert Stubbs, BA, FCA

    Robert was formally senior partner of a large independent firm of Chartered Accountants in Leeds. During 30 years he has guided many SME’s through formation to eventual disposal, raising appropriate funds for expansion and acquisitions. He is currently chair of finance for one of the largest further education colleges in Yorkshire.

    Robert is the Financial Director, a position he holds in multiple Biotech companies.


  • Elizabeth Lockett, MBA

    Elizabeth, a former oncology nurse, heads a successful drug development consultancy. She has been involved in coordinating the clinical, particularly Phase I and Phase II clinical studies, and regulatory aspects of a number of drug development projects.

    Elizabeth is the Project Coordinator and Exploitation Manager.


  • University of Strathclyde

    The University provides expert advice on Inhalosome formulation, pulmonary delivery as well as any preclinical laboratory support needed. The University team is composed of:

    • Dr Katherine Carter, Senior Lecturer in Pharmacy, Lead Investigator
    • Dr Val Ferro,PhD, co-inventor of the Inhalosomes technology
    • Professor Alex Mullan, co-inventor of the Inhalosomes technology

  • Anglia Ruskin University

    The Clinical Trials Unit (CTU) was formed in 2012 and sits within the Postgraduate Medical Institute (PMI) at Anglia Ruskin University.

    Michael Harrison, MBA, is the Director of the CTU, and will act as a trials coordinator, with a data manager and a medical statistician.


Dr Tony Lockett MBBS, MBA, PhD

Tony is a medical doctor specialising in the development of pharmaceuticals and devices.

He has worked for over 20 years in this sector, and has developed and registered many pharmaceuticals. He has considerable experience in drug development, regulatory submissions and licensing deals. He is continues to advise a number of clients on drug development in respiratory and other diseases.

Tony is the Medical Director responsible for driving and overseeing all aspects of this project.


Robert Stubbs, BA, FCA

Robert was formally senior partner of a large independent firm of Chartered Accountants in Leeds. During 30 years he has guided many SME’s through formation to eventual disposal, raising appropriate funds for expansion and acquisitions. He is currently chair of finance for one of the largest further education colleges in Yorkshire.

Robert is the Financial Director, a position he holds in multiple Biotech companies.


Elizabeth Lockett, MBA

Elizabeth, a former oncology nurse, heads a successful drug development consultancy. She has been involved in coordinating the clinical, particularly Phase I and Phase II clinical studies, and regulatory aspects of a number of drug development projects.

Elizabeth is the Project Coordinator and Exploitation Manager.


University of Strathclyde

The University provides expert advice on Inhalosome formulation, pulmonary delivery as well as any preclinical laboratory support needed. The University team is composed of:

  • Dr Katherine Carter, Senior Lecturer in Pharmacy, Lead Investigator
  • Dr Val Ferro,PhD, co-inventor of the Inhalosomes technology
  • Professor Alex Mullan, co-inventor of the Inhalosomes technology

Anglia Ruskin University

The Clinical Trials Unit (CTU) was formed in 2012 and sits within the Postgraduate Medical Institute (PMI) at Anglia Ruskin University.

Michael Harrison, MBA, is the Director of the CTU, and will act as a trials coordinator, with a data manager and a medical statistician.


Contact

Phone: +44 (0)113 3502965
Email: info@inhalosome.com

Address:
Inhalosome-C Ltd.
1 Broadgate, Floor 2 Office 2
The Headrow, Leeds
LS2 8AJ, UK

Get in Touch

Your Name (required)

Your Message